Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Third Harmonic Bio, Inc. - Common Stock (NQ: THRD )

11.71 -0.27 (-2.25%)
Streaming Delayed Price Updated: 10:43 AM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Third Harmonic Bio, Inc. - Common Stock

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Leadership Changes
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces First Quarter 2023 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases 
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases 
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
From Third Harmonic Bio
Via GlobeNewswire
Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Third Harmonic Bio
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.